Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
9 evidence topics · 9 sources
Proposed use in combination with other antihypertensive drugs
Launch-HTN: background regimen of 2 to 5 prescribed antihypertensive medications
“Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants continued taking their prescribed antihypertensive medications for the duration of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Launch-HTN: background drug classes and other medications at randomization, No. (%)
Advance-HTN: standardized background regimen of an ARB and a diuretic, with or without a calcium channel blocker
“In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Target-HTN: background therapy and excluded concomitant drugs
“Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote